Skip to main content
OpenTrials
Completed

NCT Number: NCT00534183

Metabolic Profile and Anthropometric Changes in Schizophrenia

"No clinical differences will be found between the three antipsychotics under study - olanzapine, risperidone and haloperidol - on the patients' metabolic profile and weight. "

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Metabolic Syndrome Body Weight Diabetes Diabetes Mellitus Endocrine System Diseases Glucose Metabolism Disorders Hyperinsulinism Insulin Resistance Metabolic Diseases Nutrition Disorders Nutritional and Metabolic Diseases Obesity Overnutrition Overweight Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

18 year–40 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Central Institute of Psychiatry

Ranchi, 834009, India

About this study

we aimed to study the effects of antipsychotics, olanzapine, risperidone and haloperidol on development of metabolic syndrome in a drug naïve population suffering from first episode schizophrenia and compared it with a matched healthy control group. We also aimed to examine the prevalence of metabolic syndrome as defined by the two most widely accepted definitions, the ATP IIIA and the IDF.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age between 18-40 years
  • Diagnosis of schizophrenia
  • Drug naive on admission

Exclusion criteria

  • Other psychiatric co-morbidity
  • History of severe physical illness
  • Alcohol and substance abuse or dependence
  • History of pre-existing diabetes or hypertension
  • Family history of hypertension or diabetes

Treatment and study plan

Olanzapine

Drug

Olanzapine in dose range of 10-20mg

Risperidone

Drug

Risperidone 1-6mg

Haloperidol

Drug

Haloperidol 10-20mg

Primary outcomes

  1. Study of metabolic profile

    Time frame: 6 weeks

Secondary outcomes

  1. Study of obesity and diabetes

    Time frame: 6 weeks

Sponsors and collaborators

Lead sponsor

Central Institute of Psychiatry, Ranchi, India

Other

Registry information

Acronym: MetS

Important dates

Study start
2006
Study completion
2006
First posted
Sep 24, 2007
Registry last updated
Sep 24, 2007

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.